New Delhi: Following the announcement that the NHS have accepted the revolutionary new Novartis CAR-T therapy, Kymriah, for children with leukemia, Rahael Maladwala, Pharma Analyst at GlobalData, a leading data and analytics company, offered his view on how this will impact the oncology market.
As per Mr Maladwala, “There is significant hype behind this therapy, as it offers a personalised approach to medication using the body’s own T-cells to fight cancer cells. Indeed, according to GlobalData forecasts, the Novartis CAR-T therapy, Kymriah is expected to hit over $1bn sales revenue by 2023 in the US alone. If the drug is adopted across Europe and in other countries for the indications it is in development for, the sky is the limit for the Novartis drug.”
“The NHS has moved quickly and Kymriah received funding approval in near-record time. This is indicative of the promise that the therapy holds and is likely to be the first therapy in a rapidly expanding portfolio of personalized drugs,” Mr Maladwala stated.